Scientists have uncovered a hidden reason why cancer treatments don’t work equally well for everyone. Certain drugs can ...

Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

Telmisartan, an FDA-approved blood pressure drug, could boost a certain cancer treatment's effectiveness against tumors, a ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...

Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise—and induced great disappointment. While effective at activating the immune system to kill cancer ...

In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their ...

The pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects. There is still more work to be done to refine ...

The drug can now be prescribed alongside nab-paclitaxel for patients with ovarian cancer who have relapsed between one and ...

In A Nutshell A common blood pressure drug, telmisartan, boosted the effectiveness of a cancer drug in lab and mouse studies.